Aytu BioPharma Reports Fiscal 2026 Full Year and Fourth Quarter Operational and Financial Results

Fourth-quarter fiscal 2026 net revenue rose 6.4% year over year to $16.1 million, while adjusted EBITDA was $0.5 million. Following its full commercial launch in Q3, EXXUA generated $3.9 million of Q4 revenue and 3,323 prescriptions, up about 138% sequentially; the company ended June with $26.3 million in cash.

Analysis

DERM's investment case is shifting from a dermatology cash-flow story to a specialty-CNS launch execution story, which can support multiple expansion only if prescription growth converts into durable net sales after rebates, copay support and distributor terms. The key near-term uncertainty is not demand creation but revenue quality: early prescription curves can be inflated by samples, free trials and channel fill, while the company has not disclosed net revenue per prescription, persistence, payer coverage or gross margin for EXXUA. With limited absolute EBITDA, even modest launch spending or a higher-than-expected gross-to-net adjustment could return the business to cash burn.

The non-obvious competitive issue is formulary access against generic SSRIs/SNRIs and branded alternatives such as AXSM's Auvelity; EXXUA's differentiated tolerability profile matters economically only if it reduces discontinuation and earns favorable coverage. Over the next 1-3 months, management commentary on paid-script mix, prior-authorization approval rates and repeat fills should drive the stock more than headline prescription growth. Over 6-18 months, a successful CNS launch could make DERM a more credible commercial partner or acquisition target, but failure to reach self-funding scale would raise dilution risk given micro-cap liquidity and the cost of maintaining a sales force.

Consensus may overvalue the sequential prescription percentage because the launch began from a small base. The more constructive contrarian view is that a specialty sales infrastructure already supporting dermatology products lowers incremental commercial cost versus a de novo biotech launch; therefore, evidence of stable EBITDA while EXXUA sales ramp would be disproportionately positive. Thesis is falsified if quarterly cash declines materially despite higher scripts, if net revenue per script fails to rise as paid utilization replaces launch support, or if management guides to a capital raise before EXXUA demonstrates repeat-fill traction.

Key Decisions for Investors

• Keep DERM on a 1-3 month earnings-call watchlist rather than establish a full position before payer and persistence data are disclosed. Upgrade to a small long only if management demonstrates sequential growth in paid prescriptions and confirms launch spending can be absorbed without a meaningful deterioration in quarterly cash burn.
• For a speculative 6-12 month position, use a starter long in DERM only with predefined downside discipline: exit on evidence of a near-term equity raise or two consecutive months of decelerating prescription growth. Upside requires commercial validation and potential multiple re-rating; downside is dilution and launch-cost deleveraging.
• Monitor AXSM as the cleaner liquid proxy for branded antidepressant adoption and competitive read-through. A sustained acceleration in EXXUA refill data would modestly validate demand for differentiated depression therapies, while aggressive discounting or adverse formulary commentary would be more directly negative for DERM than AXSM.
• Require three missing data points before sizing: EXXUA net sales per prescription, refill/persistence rates after the first 30-60 days, and payer-covered versus free/bridge-script mix. Without these, reported prescription growth is an operational signal, not a reliable revenue or valuation catalyst.